MAKO Surgical Corp. to Present at the Lazard Capital Markets 6th Annual Healthcare...

MAKO Surgical Corp. to Present at the Lazard Capital Markets 6th Annual
Healthcare Conference

FT. LAUDERDALE, Fla., Nov. 5, 2009 (GLOBE NEWSWIRE) -- MAKO Surgical Corp.
(Nasdaq:MAKO) announced today that Maurice R. Ferre, M.D., President and Chief
Executive Officer and Fritz L. LaPorte, Senior Vice President and Chief
Financial Officer of MAKO, will present at the Lazard Capital Markets 6th Annual
Healthcare Conference at The St. Regis in New York on Tuesday, November 17, 2009
at 4:40 pm EST.

A webcast will be available and may be accessed by visiting MAKO's website at
www.makosurgical.com under the Investor Relations section. A replay of the
webcast will be available immediately after the conclusion of the presentation.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets both its RIO(R)
Robotic-Arm Interactive Orthopedic system (RIO(R)) and its proprietary
RESTORIS(R) implants for minimally invasive orthopedic knee procedures. The MAKO
RIO is a surgeon-interactive tactile surgical platform that incorporates a
robotic arm and patient-specific visualization technology and prepares the knee
joint for the insertion and alignment of MAKO's resurfacing RESTORIS implants
through a minimal incision. The FDA-cleared RIO system allows surgeons to
provide a precise, consistently reproducible tissue-sparing, bone resurfacing
procedure called MAKOplasty(R) to a large, yet underserved patient-specific
population suffering from early to mid-stage osteoarthritic knee disease. MAKO
has an intellectual property portfolio of more than 250 licensed or owned
patents and patent applications relating to the areas of robotics, haptics,
computer assisted surgery and implants. Additional information can be found at
www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other
things, statements related to expectations, goals, plans, objectives and future
events. MAKO intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Reform Act of 1995.
In some cases, forward-looking statements can be identified by the following
words: "may," "will," "could," "would," "should," "expect," "intend," "plan,"
"anticipate," "believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing" or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain these words.
These statements are based on the current estimates and assumptions of our
management as of the date of this press release and are subject to risks,
uncertainties, changes in circumstances, assumptions and other factors that may
cause actual results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability to control
or predict. Such factors, among others, may have a material adverse effect on
MAKO's business, financial condition and results of operations and may include
the potentially significant impact of a further or continued economic downturn
on the ability of MAKO's customers to secure adequate funding to buy MAKO's
products or cause MAKO's customers to delay a purchasing decision, changes in
competitive conditions and prices in MAKO's markets, unanticipated issues
relating to product releases, decreases in sales of MAKO's principal product
lines, increases in expenditures related to increased governmental regulation or
taxation of MAKO's business, unanticipated issues in securing regulatory
clearance or approvals for upgrades or changes to MAKO's products, unanticipated
issues associated with any healthcare reform that may be enacted, loss of key
management and other personnel or inability to attract such management and other
personnel and unanticipated intellectual property expenditures required to
develop and market MAKO's products. These and other risks are described in
greater detail under "Risk Factors" in MAKO's periodic reports filed from time
to time with the Securities and Exchange Commission. Given these uncertainties,
undue reliance should not be placed on these forward-looking statements. MAKO
does not undertake any obligation to release any revisions to these
forward-looking statements publicly to reflect events or circumstances after the
date of this press release or to reflect the occurrence of unanticipated events.

"MAKOplasty(R)," "RESTORIS(R)" and "RIO(R)," as well as the "MAKO" logo, whether
standing alone or in connection with the words "MAKO Surgical Corp." are
trademarks of MAKO Surgical Corp.

-0-
CONTACT: MAKO Surgical Corp.
Investors:
Susan M. Verde
954-927-2044 x349
sverde@makosurgical.com

Westwicke Partners
Mark Klausner
443-213-0500
mark.klausner@westwicke.com